Anthropic Acquires Single-Person Biotech Company Mithril Medicine, Launches In-House Drug Development Program

According to TechFlow, as reported by TNW on October 28, Anthropic announced in a Tuesday blog post the acquisition of Mithril Medicine. The company has only one employee and is developing therapies for two rare forms of muscular dystrophy. Deal terms were not disclosed, and founder Cody Tranbarger has joined Anthropic. According to Anthropic, Mithril leveraged Claude to manage contracts, logistics, and experiments with 11 external laboratories, advancing the candidate therapy from concept to positive results in mouse trials in less than 18 months. According to its technical report, which has not yet undergone peer review, mice treated with an antibody design exhibited grip strength approximately double that of untreated mice. If the candidate drug maintains stable efficacy, it could enter human clinical trials as early as the end of 2028.